View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
May 25, 2017updated 07 Aug 2019 2:54pm

Will acne be the next indication to benefit from biologics?

In the US, 56.4 million people are believed to have acne and it affects more than twice as many people as psoriasis and atopic dermatitis combined. However, while new and innovate products have revolutionised the treatment of these two conditions, developments in the treatment of acne have not managed to keep up.

In the US, 56.4 million people are believed to have acne and it affects more than twice as many people as psoriasis and atopic dermatitis combined. However, while new and innovate products have revolutionised the treatment of these two conditions, developments in the treatment of acne have not managed to keep up.

The first biologic drugs for psoriasis were approved in 2003, and since then a number of biologics have made it to market.

In 2017, Dupixent became the first biologic to be approved for atopic dermatitis. It is expected to benefit patients whose disease is not adequately controlled with topical prescription therapies.

Unlike topical therapies, biologics target the patient’s immune system directly, meaning they are are associated with fewer side effects and are more effective.

What next for acne?

Acne patients could potentially benefit in the near future from the approval of Dermia’s Olumacostat Glasaretil, a small molecule drug designed to target excessive sebum production. This is currently undergoing Phase III trials and results are expected to be published in the first half of 2018.

If these trials are successful Dermira expects to start marketing the drug in 2019. However, people with the condition will need to wait for acne-treating biologics to reach the market.

But what about biologics?

It is possible that a biologic will be approved for acne at some point between now and 2023, but a date closer to the end of this period would be most likely.

There are currently ten biologic products in the acne pipeline, but only three are in clinical development. One of these, AOBiomeLLC’s B-244, is at Phase III. 

Acne patients are often reluctant to seek treatment, as current options are associated with poor effectiveness or severe adverse effects. A company that can succeed in bringing a biologic to market that can effectively treat the condition while minimising side effects would be able to command high revenues and capture a large share of the dermatology market. 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena